Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

SCCHN

Bristol-Myers Squibb (BMS) building

BMS ends development of Alzheimer’s candidate avagacestat

Amyloid-targeting candidate fails to make it to phase III trials

- PMLiVE

Eliquis cleared in EU for stroke prevention in AF

Follows last year’s approval for the prevention of VTE after surgery for BMS and Pfizer's drug

- PMLiVE

EU approval for AZ/BMS’ first-in-class diabetes drug Forxiga

First SGLT2 inhibitor to be approved for marketing anywhere in the world

- PMLiVE

BMS’ Orencia matches Humira in trial

Head-to-head study shows subcutaneous version as effective as Abbott's drug

Bristol-Myers Squibb (BMS) building

BMS cuts salesforce on revised Abilify deal

Nearly 500 jobs to go as US rights to schizophrenia blockbuster return to Otsuka

- PMLiVE

Discounts persuade NICE to recommend skin cancer drugs Yervoy and Zelboraf

Roche and BMS offer patient access schemes for NHS use of drugs

- PMLiVE

More action needed to prevent AF-related strokes

Bayer-sponsored report says Europe is heading for a ‘stroke crisis’

Bristol-Myers Squibb (BMS) building

BMS slides to loss as Plavix revenues dry up

Records net loss of $711m during third quarter

Frances Heller joins BMS senior management

Takes up business development role and will report to Lamberto Andreotti

FDA sets new date for Eliquis review in atrial fibrillation

US regulator had asked for more data from Pfizer and BMS

Bristol-Myers Squibb (BMS) building

BMS halts hep C candidate development after patient death

Promises to share drug data to assist other pharma companies’ patient safety measures

Bristol-Myers Squibb (BMS) building

BMS halts trial of hepatitis C drug on safety issues

At least one person in study thought to have developed congestive heart failure

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links